https://www.selleckchem.com/products/u73122.html
To describe the baseline participant characteristics in the ASPREE-AMD study, investigating the effect of aspirin on AMD incidence and progression. Australian participants from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, randomized to 100mg aspirin daily or placebo, had non-mydriatic, digital color fundus images graded according to the Beckman AMD classification. Associations with AMD were determined for baseline characteristics and genetic risk variants. ASPREE-AMD sub-study enrolled 4993 participants with gradable mac
Like
Comment
Share
